Drugs / Guanfacine ER
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05273567 | Jun 2022 → Jul 2024 | cannabis dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2 | NCT03764098 | Aug 2020 → Aug 2026 overdue | alcohol-related disorders | Yale University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | guanfacine-er | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05273567 ↗ |
| Route | Oral | “Administered orally twice daily” NCT03764098 ↗ |